Oncolytic Virus Cancer Immunotherapy and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Oncolytic Virus Cancer Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oncolytic Virus Cancer Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oncolytic Virus Cancer Immunotherapy Overall Market Size
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size: 2023 VS 2030
2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oncolytic Virus Cancer Immunotherapy Players in Global Market
3.2 Top Global Oncolytic Virus Cancer Immunotherapy Companies Ranked by Revenue
3.3 Global Oncolytic Virus Cancer Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Oncolytic Virus Cancer Immunotherapy Companies in Global Market, by Revenue in 2023
3.5 Global Companies Oncolytic Virus Cancer Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Oncolytic Virus Cancer Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oncolytic Virus Cancer Immunotherapy Market Size Markets, 2023 & 2030
4.1.2 Monoclonal Antibodies
4.1.3 Checkpoint Inhibitors
4.1.4 Oncoloytic Viral Therapies and Cancer Vaccines
4.2 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
4.2.2 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
4.2.3 By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oncolytic Virus Cancer Immunotherapy Market Size, 2023 & 2030
5.1.2 Lung Cancer
5.1.3 Breast Cancer
5.1.4 Colorectal Cancer
5.1.5 Melanoma
5.1.6 Prostate Cancer
5.1.7 Head and neck Cancer
5.1.8 Ovarian Cancer
5.1.9 Pancreatic Cancer
5.1.10 Others
5.2 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
5.2.2 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
5.2.3 By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Oncolytic Virus Cancer Immunotherapy Market Size, 2023 & 2030
6.2 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2024
6.2.2 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue, 2025-2030
6.2.3 By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.3.2 US Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.3.3 Canada Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.3.4 Mexico Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.4.2 Germany Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.3 France Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.4 U.K. Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.5 Italy Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.6 Russia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.7 Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.4.8 Benelux Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.5.2 China Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.3 Japan Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.4 South Korea Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.5 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.5.6 India Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.6.2 Brazil Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.6.3 Argentina Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030
6.7.2 Turkey Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.3 Israel Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.4 Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
6.7.5 UAE Oncolytic Virus Cancer Immunotherapy Market Size, 2019-2030
7 Oncolytic Virus Cancer Immunotherapy Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.1.4 AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.2.4 Amgen Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.2.5 Amgen Key News & Latest Developments
7.3 F Hoffman-La Roche
7.3.1 F Hoffman-La Roche Company Summary
7.3.2 F Hoffman-La Roche Business Overview
7.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.3.4 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.3.5 F Hoffman-La Roche Key News & Latest Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.4.4 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.4.5 Bristol-Myers Squibb Key News & Latest Developments
7.5 Novartis AG
7.5.1 Novartis AG Company Summary
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.5.4 Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.5.5 Novartis AG Key News & Latest Developments
7.6 Merck & Co., Inc.
7.6.1 Merck & Co., Inc. Company Summary
7.6.2 Merck & Co., Inc. Business Overview
7.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.6.4 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.6.5 Merck & Co., Inc. Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.7.4 Pfizer Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.7.5 Pfizer Key News & Latest Developments
7.8 Biovex
7.8.1 Biovex Company Summary
7.8.2 Biovex Business Overview
7.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.8.4 Biovex Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.8.5 Biovex Key News & Latest Developments
7.9 Cell Genesys
7.9.1 Cell Genesys Company Summary
7.9.2 Cell Genesys Business Overview
7.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.9.4 Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.9.5 Cell Genesys Key News & Latest Developments
7.10 Crusade Laboratories
7.10.1 Crusade Laboratories Company Summary
7.10.2 Crusade Laboratories Business Overview
7.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.10.4 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.10.5 Crusade Laboratories Key News & Latest Developments
7.11 Genelux Corporation
7.11.1 Genelux Corporation Company Summary
7.11.2 Genelux Corporation Business Overview
7.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.11.4 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.11.5 Genelux Corporation Key News & Latest Developments
7.12 Lokon Pharma
7.12.1 Lokon Pharma Company Summary
7.12.2 Lokon Pharma Business Overview
7.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.12.4 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.12.5 Lokon Pharma Key News & Latest Developments
7.13 MultiVir
7.13.1 MultiVir Company Summary
7.13.2 MultiVir Business Overview
7.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Major Product Offerings
7.13.4 MultiVir Oncolytic Virus Cancer Immunotherapy Revenue in Global Market (2019-2024)
7.13.5 MultiVir Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Oncolytic Virus Cancer Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Oncolytic Virus Cancer Immunotherapy Market Drivers in Global Market
Table 3. Oncolytic Virus Cancer Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Oncolytic Virus Cancer Immunotherapy in Global Market
Table 5. Top Oncolytic Virus Cancer Immunotherapy Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Oncolytic Virus Cancer Immunotherapy Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Companies, 2019-2024
Table 8. Global Companies Oncolytic Virus Cancer Immunotherapy Product Type
Table 9. List of Global Tier 1 Oncolytic Virus Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oncolytic Virus Cancer Immunotherapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Oncolytic Virus Cancer Immunotherapy Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2025-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 32. AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 36. Amgen Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 37. Amgen Key News & Latest Developments
Table 38. F Hoffman-La Roche Company Summary
Table 39. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 40. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 41. F Hoffman-La Roche Key News & Latest Developments
Table 42. Bristol-Myers Squibb Company Summary
Table 43. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 44. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 45. Bristol-Myers Squibb Key News & Latest Developments
Table 46. Novartis AG Company Summary
Table 47. Novartis AG Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 48. Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 49. Novartis AG Key News & Latest Developments
Table 50. Merck & Co., Inc. Company Summary
Table 51. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 52. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 53. Merck & Co., Inc. Key News & Latest Developments
Table 54. Pfizer Company Summary
Table 55. Pfizer Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 56. Pfizer Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 57. Pfizer Key News & Latest Developments
Table 58. Biovex Company Summary
Table 59. Biovex Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 60. Biovex Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 61. Biovex Key News & Latest Developments
Table 62. Cell Genesys Company Summary
Table 63. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 64. Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 65. Cell Genesys Key News & Latest Developments
Table 66. Crusade Laboratories Company Summary
Table 67. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 68. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 69. Crusade Laboratories Key News & Latest Developments
Table 70. Genelux Corporation Company Summary
Table 71. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 72. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 73. Genelux Corporation Key News & Latest Developments
Table 74. Lokon Pharma Company Summary
Table 75. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 76. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 77. Lokon Pharma Key News & Latest Developments
Table 78. MultiVir Company Summary
Table 79. MultiVir Oncolytic Virus Cancer Immunotherapy Product Offerings
Table 80. MultiVir Oncolytic Virus Cancer Immunotherapy Revenue (US$, Mn) & (2019-2024)
Table 81. MultiVir Key News & Latest Developments
List of Figures
Figure 1. Oncolytic Virus Cancer Immunotherapy Segment by Type in 2023
Figure 2. Oncolytic Virus Cancer Immunotherapy Segment by Application in 2023
Figure 3. Global Oncolytic Virus Cancer Immunotherapy Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Oncolytic Virus Cancer Immunotherapy Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2023
Figure 8. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 9. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 10. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 12. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 14. By Region - Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 15. By Country - North America Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 16. US Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 20. Germany Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 21. France Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 28. China Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 32. India Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 34. Brazil Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Oncolytic Virus Cancer Immunotherapy Revenue Market Share, 2019-2030
Figure 37. Turkey Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Oncolytic Virus Cancer Immunotherapy Revenue, (US$, Mn), 2019-2030
Figure 41. AstraZeneca Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Amgen Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Novartis AG Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Pfizer Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Biovex Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Cell Genesys Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. MultiVir Oncolytic Virus Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Industry Market Size
